All links to Gospa News articles have been added aftermath for relevance to the topics covered
by Fraiser Kansteiner – originally published on Fierce Pharma
As parallel litigation simmers in the U.S., Germany and the Netherlands, the United Kingdom’s High Court has set the venue for one of Pfizer and Moderna’s first skirmishes in a heated battle over COVID-19 vaccine patents.
The case, comprising dueling lawsuits from the mRNA rivals, is set to go to trial in London in April 2024, multiple news outlets report.
Spikevax maker Moderna sued Pfizer and BioNTech in the U.K. last September, seeking compensation and damages for sales of the partners’ rival mRNA shot Comirnaty. Moderna claims Pfizer’s vaccine flouts patents related to lipid nanoparticle delivery, spike protein encoding and more.
Not content to play sitting duck, Pfizer and BioNTech parried with their own U.K. case challenging the validity of Moderna’s COVID-19 vaccine patents.
Pfizer did not immediately respond to Fierce Pharma’s request for comment on the latest litigation update. Moderna, for its part, said it did not have a statement at this time.
The case is of “considerable value and importance” to the companies, Andrew Waugh, for Moderna, said in court documents quoted by The Independent. Experiments and expert testimony from biochemists, immunologists, virologists and vaccine delivery experts may be needed to resolve the dispute, the court was told at a preliminary hearing Thursday.
The mRNA kerfuffle has largely played out the same in the U.S., where Moderna first sued Pfizer in August. At the time, Moderna CEO Stéphane Bancel argued his company was trying to “protect the innovative mRNA technology that we pioneered, invested billions of dollars into creating, and patented during the decade preceding the COVID-19 pandemic.”
In a unique twist, Moderna said it wouldn’t seek to remove Pfizer and BioNTech’s shot from the playing field. Instead, in developed markets, Moderna said it expected its mRNA rivals to “respect its intellectual property rights” and “consider a commercially reasonable license.” Moderna added that it would keep away from Comirnaty sales in many low- and middle-income countries.
Pfizer and BioNTech hit back with a countersuit in December, demanding a jury trial and refuting Moderna’s infringement claims. The partners contended Moderna was stretching its “already overbroad” and arguably “invalid” patents and was trying to “claim credit for others’ work.”
The companies argued that Moderna, in its original lawsuit, tried to rewrite the well-known story of the COVID-19 pandemic to put itself in the “single, starring role” by ignoring the contributions of other players.
by Fraiser Kansteiner – originally published on Fierce Pharma
Fabio is Director and Editor of Gospa News; a Christian Information Journal.
Fabio Giuseppe Carlo Carisio, born on 24/2/1967 in Borgosesia, started working as a reporter when he was only 19 years old in the alpine area of Valsesia, Piedmont, his birth region in Italy. After studying literature and history at the Catholic University of the Sacred Heart in Milan, he became director of the local newspaper Notizia Oggi Vercelli and specialized in judicial reporting.
For about 15 years he is a correspondent from Northern Italy for the Italian newspapers Libero and Il Giornale, also writing important revelations on the Ustica massacre, a report on Freemasonry and organized crime.
With independent investigations, he collaborates with Carabinieri and Guardia di Finanza in important investigations that conclude with the arrest of Camorra entrepreneurs or corrupt politicians.
In July 2018 he found the counter-information web media Gospa News focused on geopolitics, terrorism, Middle East, and military intelligence.
His articles were published on many international media and website as SouthFront, Reseau International, Sputnik Italia, United Nation Association Westminster, Global Research, Kolozeg and more…
His investigations was quoted also by The Gateway Pundit, Tasnim and others
He worked for many years for the magazine Art & Wine as an art critic and curator.
ATTENTION READERS
We See The World From All Sides and Want YOU To Be Fully InformedIn fact, intentional disinformation is a disgraceful scourge in media today. So to assuage any possible errant incorrect information posted herein, we strongly encourage you to seek corroboration from other non-VT sources before forming an educated opinion.
About VT - Policies & Disclosures - Comment Policy
